title: [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
abstract: We conducted a multicenter postmarketing study to investigate the efficacy and safety of reinduction therapy with a high-dose cytarabine-containing regimen for pediatric patients with relapsed or refractory acute leukemia. Seven of 13 patients (53.8%) with ALL achieved complete or partial remission, and only 1 of 6 patients (16.7%) with AML achieved partial remission. The frequent non-hematologic adverse events were gastrointestinal toxicities, such as vomiting, diarrhea and abdominal pain, as well as pyrexia and headache. Infection appeared in 9 of 20 (45%) patients. There were two death during reinduction therapy. One died of invasive bronchopulmonary aspergillosis, and the other died of intracranial hemorrhage and renal failure. These results indicated that a high-dose cytarabine regimen is effective as reinduction therapy in pediatric patients with relapsed ALL, and supportive care is essential to prevent or control treatment-related adverse events, such as infection.
authors.affiliation: Division of Hematology and Oncology, Shizuoka Children's Hospital.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Horikoshi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Mikiya
authors.initials: M
authors.lastname: Endo
authors.forename: Arata
authors.initials: A
authors.lastname: Watanabe
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kikuta
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Koike
authors.forename: Ryoji
authors.initials: R
authors.lastname: Hanada
authors.forename: Ryota
authors.initials: R
authors.lastname: Hosoya
authors.forename: Akira
authors.initials: A
authors.lastname: Ohara
authors.forename: Koichiro
authors.initials: K
authors.lastname: Ikuta
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Goto
authors.forename: Keiko
authors.initials: K
authors.lastname: Asami
authors.forename: Kanji
authors.initials: K
authors.lastname: Sugita
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
authors.forename: Masahito
authors.initials: M
authors.lastname: Tsurusawa
authors.forename: Toshinari
authors.initials: T
authors.lastname: Hori
authors.forename: Junichi
authors.initials: J
authors.lastname: Hara
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nishimura
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nagatoshi
authors.forename: Hideo
authors.initials: H
authors.lastname: Mugishima
authors.forename: Shigeru
authors.initials: S
authors.lastname: Ohta
authors.forename: Souichi
authors.initials: S
authors.lastname: Adachi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tsukimoto
mesh_terms: D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D055744:Invasive Pulmonary Aspergillosis / Q000209:etiology / Q000517:prevention & control; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine